Gilead Sciences Inc
Change company Symbol lookup
Select an option...
GILD Gilead Sciences Inc
FUAPF Global Cannabis Applications Corp
GXG Global X MSCI Colombia ETF
ATMR Altimar Acquisition Corp II
AMD Advanced Micro Devices Inc
BC-A BRUNSWICK 6 500 SENIOR NTS
WST West Pharmaceutical Services Inc
ITT ITT Inc
PLBY Plby Group Inc
SVFA SVF Investment Corp
Go

Health Care : Biotechnology | Large Cap Value
Company profile

Gilead Sciences, Inc. is a biopharmaceutical company that is focused on advancing medicines to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company's portfolio of products and pipeline of investigational drugs includes treatments for HIV/acquired immune deficiency syndrome (AIDS), COVID-19, liver diseases, hematology/oncology/cell therapy and other. Its products for HIV/AIDS patients include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada and Atripla. It offers Veklury to patients with COVID-19. The Company's products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Viread and Vosevi. Its products under hematology/oncology/cell therapy include Yescarta, Tecartus, Trodelvy and Zydelig. Other products include Letairis, Ranexa and AmBisome. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. The Company operates in more than 335 countries worldwide.

Closing Price
$71.61
Day's Change
0.28 (0.39%)
Bid
--
Ask
--
B/A Size
--
Day's High
71.76
Day's Low
70.44
Volume
(Heavy Day)
Volume:
10,888,341

10-day average volume:
6,799,567
10,888,341

GILD's position in the Biotechnology industry

Industry PeersGILDABBVAMGNREGNVRTX

Summary

Company ProfileGilead Sciences, Inc. is a biopharmaceutical company that is focused on advancing medicines to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer...
AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. AbbVie...
Go to ABBV summary
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products...
Go to AMGN summary
Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious diseases. The Company...
Go to REGN summary
Vertex Pharmaceuticals Incorporated is a biotechnology company. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research...
Go to VRTX summary
52-Week Change

VS. INDUSTRY
10.10%
20.19%
-11.57%
15.38%
-30.63%
Market Cap

VS. INDUSTRY
$89.8B
$190.4B
$124.6B
$69.7B
$48.9B
Beta

VS. INDUSTRY
0.4
0.8
0.7
0.2
0.6
Dividend Yield

VS. INDUSTRY
3.97%
4.83%
3.21%
--
--
P/E (TTM, GAAP)

VS. INDUSTRY
17.58x
29.00x
22.31x
11.70x
24.82x
Data as of

Fundamentals

Total Revenue (TTM)

VS. INDUSTRY
$26.6B
$53.7B
$25.5B
$12.4B
$6.7B
Profit Margin

VS. INDUSTRY
19.28%
12.42%
22.55%
50.11%
29.80%
Earnings Growth
(5 year, GAAP)

VS. INDUSTRY
-61.76%
-2.82%
6.33%
40.78%
--
Revenue Growth (TTM)

VS. INDUSTRY
20.13%
48.31%
4.87%
60.97%
23.71%
Data as of
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Copyright © 2021. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.